Clinical trial Recruiting at 1 site Interventional Ages 18 and up Women only

Combining radiation and hyperthermia for advanced cervical cancer treatment

Official title: Multimodal Therapy of Advanced Cervical Cancer With Radiotherapy or Chemoradiation, Interstitial Brachytherapy in Combination With Hyperthermia

Run by University of Erlangen-Nürnberg Medical School · NCT03249519 · Data updated 2026-11-12

This study tests if combining radiation therapy and heat treatment can improve outcomes for people with advanced cervical cancer.

Quick facts

Study typeInterventional
Ages18 Years and up
SexWomen only
Enrollment999 (estimated)
SponsorUniversity of Erlangen-Nürnberg Medical School
Academic / other
Drugs / interventionsradiation
Locations1 site (Erlangen)
StatusRecruiting
StartedAugust 1, 2017
Main results expectedDecember 31, 2094
Study endsDecember 31, 2099
Registry record updatedAugust 15, 2017
Trial IDNCT03249519 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older with histologically confirmed cervical cancer at FIGO stages IIB to IVA.

Probably not a fit

Patients with uncontrolled cardiac conditions or those who are pregnant or lactating may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of combining radiation therapy or chemoradiation with interstitial brachytherapy and hyperthermia in patients with advanced cervical cancer. The aim is to enhance the treatment outcomes by leveraging the radio- and chemosensitive effects of hyperthermia. Eligible participants include those with histologically confirmed cervical carcinoma at specific stages, and the study will assess the clinical outcomes of this combined approach. The interventions include radiation, brachytherapy, Cisplatin, and hyperthermia.

Why it matters

Potential benefit: If successful, this approach could significantly improve treatment outcomes for patients with advanced cervical cancer.

How similar studies have gone: Other studies have shown promising results with similar combinations of therapies, indicating potential for success.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Histological confirmed carcinoma of the Cervix
* FIGO-Stage IIB-IVA; earlier stages when inoperable or according to patient's wish
* clinical M0; except: involvement of para-aortic lymph nodes
* Age ≥ 18 years
* ECOG ≤ 2
* Informed consent of the patient

Exclusion Criteria:

* Pre-existing uncontrolled cardiac disease, signs of cardiac failure, or rhythm disturbances requiring therapy
* Cardiac Pacemaker
* Myocardial infarction within the past 12 months
* Congestive heart failure
* Complete bundle branch block
* New York Heart Association (NYHA) class III or IV heart disease
* Disease that would preclude chemoradiation or deep regional hyperthermia
* Metal implants (length \> 2cm or dense clusters of marker clips in the pelvis)
* Active or therapy-resistent bladder infections
* Pre-existing or concommitant immunodeficiency Syndrome
* Pregnant or lactating women
* Patients not willing to use effective contraception during and up to 6 months after therapy

Where it's running

  • Universitätsklinikum Erlangen, Strahlenklinik
    Erlangen, Germany
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.